The reaction is decidedly mixed, with lots of strong opinions on both sides, according to an anonymous survey conducted by Mizuho Securities.
While one investor said Viehbacher was a “value destroyer at Sanofi” and another added that he’s “never done much,” there also was effusive praise for his work at the French pharma giant, which he guided from 2008 to 2014.
“He turned Sanofi around, including doing a smart deal with Genzyme,” said one supporter, who also called Biogen’s new chief a “very strong communicator.”
